McKesson invested USD 1.4 billion in Option Care. McKesson stock gains 2.14 percent

Published on 10/12/2026 at 11:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson will hold 49.00 percent after closing. McKesson stock costs EUR 838.40 on October 12, 2026, 2.14 percent above the EUR 820.80 Xetra close.

Key points in brief

McKesson invested USD 1.4 billion for a 49.00 percent minority stake in Option Care Health.
The Option Care transaction has an enterprise value of USD 5.8 billion and is expected to close in the first half of 2027.
McKesson stock was trading at EUR 838.40 at Lang & Schwarz on October 12, 2026, 2.14 percent above the EUR 820.80 Xetra close of October 9, 2026.
McKesson reaffirmed fiscal 2027 adjusted earnings per share guidance of USD 44.20-45.00 on October 1, 2026.

Schwarzweißfoto eines Lagerarbeiters mit Wagen voller Kartons in großer Lagerhalle — Schwarzweiß-Reportagefoto dokumentiert McKesson Corporation ISIN US58155Q1031 im täglichen Logistikbetrieb mit Arbeiter im Pharma-Vertriebslager, Illustration mit AI erstellt.

McKesson invested USD 1.4 billion for a 49.00 percent minority stake in Option Care Health under an agreement announced on October 6, 2026, according to McKesson. At 11:23 a.m. CEST on October 12, 2026, McKesson stock was trading at EUR 838.40 at Lang & Schwarz, 2.14 percent above the EUR 820.80 Xetra close of October 9, 2026.

Option Care adds specialty care exposure

The transaction gives McKesson exposure to Option Care Health, an independent provider of home and alternate-site infusion services. The total enterprise value is USD 5.8 billion, while Clayton Dubilier & Rice will hold approximately 51.00 percent and McKesson approximately 49.00 percent, according to the October 6 release.

Reuters reported on October 6, 2026, that the deal values Option Care Health at USD 5.8 billion including debt and gives McKesson a minority interest. The structure also gives McKesson a framework to purchase CD&R's remaining stake later, subject to specified conditions.

Three dated milestones shape the story

On August 5, 2026, McKesson reported first-quarter fiscal 2027 revenue of USD 105.38 billion, according to Stock Analysis. Revenue was up 7.70 percent from the comparable period, giving the October transaction a larger operating base.

On October 1, 2026, McKesson extended its pharmaceutical distribution partnership with CVS Health through June 2032 and reaffirmed fiscal 2027 adjusted earnings per share guidance of USD 44.20-45.00, as Business Wire reported.

The October 6 Option Care agreement is the latest milestone and carries a distinct earnings implication: McKesson intends to account for its minority interest using the equity method, with its share of Option Care Health's net income or loss recorded in other income. That accounting treatment makes the investment's future contribution dependent on the acquired business's performance.

What dates matter next?

McKesson is scheduled to release second-quarter fiscal 2027 results after market close on November 4, 2026, with its investor webcast set for 4:30 p.m. ET. The Option Care transaction is expected to close in the first half of calendar year 2027, subject to stockholder and regulatory approvals.

Stock holds above the Xetra close

McKesson stock was trading at EUR 838.40 at Lang & Schwarz on October 12, 2026 at 11:23 a.m. CEST, up EUR 17.60 or 2.14 percent versus the Xetra close of EUR 820.80 on October 9, 2026. The primary NYSE listing was last quoted at USD 938.84 on October 9, 2026 at 4:00 p.m. ET, with a 52-week range of USD 723.68 to USD 999.00 and market capitalization of USD 109.9 billion.

The further course of trading is shown by the continuously updated real-time quote of McKesson stock.